Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as
first line therapy in patients with triple-negative MBC. 80 patients will be treated into
this study.